Skip to main
PTCT

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTC Therapeutics (PTCT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 10%

Bulls say

PTC Therapeutics is a success story in the biopharmaceutical industry, with its launch of Sephience and votoplam leading to high compliance and positive patient feedback. With a potential stock value of $74 to $174 in the U.S. and EU5 market and a promising new treatment for Huntington's disease in development, PTC has potential for future growth. However, the company also faces challenges in international markets, making it important for PTC to continue to perform above current estimates.

Bears say

PTC Therapeutics is currently facing challenges that may hinder its future growth. The company's lead product, Translarna, has faced setbacks in its clinical trials and may not receive regulatory approval. In addition, the company's pipeline is heavily focused on rare diseases, which may limit its market potential. These factors, along with the high valuation of the stock, lead to a negative outlook on PTC Therapeutics's stock.

PTC Therapeutics (PTCT) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of PTC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PTC Therapeutics (PTCT) Forecast

Analysts have given PTC Therapeutics (PTCT) a Buy based on their latest research and market trends.

According to 10 analysts, PTC Therapeutics (PTCT) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PTC Therapeutics (PTCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.